Augmentin (Co-amoxiclav) Oral
آگمینٹن
QUALITATIVE AND QUANTITATIVE COMPOSITION:
AUGMENTIN 375 mg tablets: Also for the Each tablet contains 250 mg Amoxycillin (as the Amoxycillin trihydrate U.S.P.) and 125 mg clavulanic acid (as the potassium salt B .Each tablet contains 500 mg. Amoxycilliri (as the Amoxycillin trihydrate U.S.P.) and 125 mg clavulanic acid (as the potassium salt B.
CLINICAL PARTICULARS:
Also for the in to be Upper respiratory tract infections (including ENT) e.g.repetitive tonsillitis, sinusitis, otitis media, regularly brought about by Streptococcus pneumoniae, Haemophi influenzae, Moraxella catarrhalis and Streptococcus pyogenes. Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis (AECB), (AECOPD), lobar and bronchopneumonia, typically caused by Streptococc.
Helplessness to AUGMENTIN, will change with geology and time. Also for Local susceptibility data should be consulted where available, and microbiological sampling a
susceptibility testing performed where necessary.
Dosage and Administration:
Also for the in To be minimise potential gastrointestinal intolerance, administer at the start of a meal.
Adults and Children over 12 years:
Mild-Moderate infections: One AUGMENTIN 375 mg tablet every 8 hours or One AUGMENTIN 625 mg tablet every 12 hours, Severe infections: Also foe the One AUGMENTIN 1 g tablet every 12 hours or One AUGMENTIN 625 mg tablet every 8 hours or Two AUGMENTIN 375 mg tablets every 8 hour.
Children:
The usual recommended daily dosage is:
The tables underneath give measurement direction for youngsters.
AUGMENTIN also for the is contra-indicated in patients with a history of hypersensitivity to beta-lactams, e g. also for the penicillins and cephalosporins, AUGMENTIN is contra-indicated in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction
Probenecid diminishes the renal rounded discharge of amoxycillin .There are no information on the corresponding utilization of AUGMENTIN and allopurinol.
Also for the in Reproduction studies in animals (mice and rats) with orally and parenterally administered AUGMENTIN have shown no teratogenic effects.
Infections and infestations:
Common Mucocutaneous candidiasis
Blood and lymphatic system disorders:
Rare Reversible leucopenia (including neutropenia) and thrombocytopenia.
Exceptionally interesting Reversible hyperactivity, aseptic meningitis, seizures. Seizures might happen in patients with weakened renal capability or in those getting high portions.
Immune system disorders
Nervous system disorders
Uncommon Dizziness, headache
Very rare Reversible hyperactivity, aseptic meningitis, convulsions. Spasms might happen in patients with debilitated renal capability or in those getting high portions.
Very rare Kounis syndrome
Gastrointestinal disorders
Adults
Very common Diarrhoea; Common hausea, vomiting
Children Common Diarrhoea, nausea, vomiting
Uncommon Indigestion
Anti-toxin related colitis (counting pseudomembranous colitis and haemorrhagic colitis), drug-incited enterocolitis condition – (see Alerts and Precautionary measures). Dark bushy tongue.
Very rare Hepatitis and cholestatic jaundice.
Skin and subcutaneous tissue disorders:
Uncommon Skin rash, pruritus, urticaria
Erythema multiforme
Very rare
Linear IgA disease.
Very rare Interstitial nephritis, crystalluria (see Overdose)
Overdose:
Gastrointestinal side effects and aggravation of the liquid and electrolyte adjusts might be clear
خوراک اور طریقہ استعمال:
Special Precautions for Storage
Also for the take after the expiry date shown on the pack.
ڈاکٹر کی ہدایت کے مطابق استعمال کریں
Refer to pack for storage temperature.
AUGMENTIN tablet packs contain in a form of dessiflex foil.
Not all presentations are available in every country. Version number: GDS28/IP/18 Date of issue: 23 February 2023
خشک جگہ پر ۲۵ سینٹی گریڈ سے کم درجہ حرارت پر رکھیں تمام ادویات بچوں کی پہنچ سے دور رکھیں صرف کھانے پینے کے لئے استعمال کریں
gsk
GlaxoSmithKline
Manufactured by:
GlaxoSmithKline Pakistan Limited F/268, S.I.T.E., Karachi.